# A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

> **NCT01313637** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1493 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK573719/GW642444 125/25mcg
- **DRUG:** GSK573719 125mcg
- **DRUG:** GW642444 25mcg
- **DRUG:** Placebo only

## Key facts

- **NCT ID:** NCT01313637
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-01
- **Primary completion:** 2012-03-01
- **Final completion:** 2012-04-19
- **Target enrollment:** 1493 (ACTUAL)
- **Last updated:** 2018-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313637, "A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01313637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*